» Articles » PMID: 18996184

Evidence for NQO2-mediated Reduction of the Carcinogenic Estrogen Ortho-quinones

Overview
Date 2008 Nov 11
PMID 18996184
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The physiological function of NAD(P)H:quinone oxidoreductase (NQO1, DT-diaphorase) is to detoxify potentially reactive quinones by direct transfer of two electrons. A similar detoxification role has not been established for its homologue NRH:quinone oxidoreductase 2 (NQO2). Estrogen quinones, including estradiol(E(2))-3,4-Q, generated by estrogen metabolism, are thought to be responsible for estrogen-initiated carcinogenesis. In this investigation, we have shown for the first time that NQO2 catalyzes the reduction of electrophilic estrogen quinones and thereby may act as a detoxification enzyme. ESI and MALDI mass spectrometric binding studies involving E(2)-3,4-Q with NQO2 clearly support the formation of an enzyme-substrate physical complex. The problem of spontaneous reduction of substrate by cofactor, benzyldihydronicotinamide riboside (BNAH), was successfully overcome by taking advantage of the ping-pong mechanism of NQO2 catalysis. The involvement of the enzyme in the reduction of E(2)-3,4-Q was further supported by addition of the inhibitor quercetin to the assay mixture. NQO2 is a newly discovered binding site (MT3) of melatonin. However, addition of melatonin to the assay mixture did not affect the catalytic activity of NQO2. Preliminary kinetic studies show that NQO2 is faster in reducing estrogen quinones than its homologue NQO1. Both UV and liquid chromatography-tandem mass spectrometry assays unequivocally corroborate the reduction of estrogen ortho-quinones by NQO2, indicating that it could be a novel target for prevention of breast cancer initiation.

Citing Articles

Polymorphisms and Pharmacogenomics of : The Past and the Future.

Janda E, Boutin J, De Lorenzo C, Arbitrio M Genes (Basel). 2024; 15(1).

PMID: 38254976 PMC: 10815803. DOI: 10.3390/genes15010087.


Afzelin induces immunogenic cell death against lung cancer by targeting NQO2.

Xia L, Xu X, Li M, Zhang X, Cao F BMC Complement Med Ther. 2023; 23(1):381.

PMID: 37891619 PMC: 10605937. DOI: 10.1186/s12906-023-04221-3.


Specific quinone reductase 2 inhibitors reduce metabolic burden and reverse Alzheimer's disease phenotype in mice.

Gould N, Scherer G, Carvalho S, Shurrush K, Kayyal H, Edry E J Clin Invest. 2023; 133(19).

PMID: 37561584 PMC: 10541198. DOI: 10.1172/JCI162120.


3-Arylidene-2-oxindoles as Potent NRH:Quinone Oxidoreductase 2 Inhibitors.

Lozinskaya N, Bezsonova E, Dubar M, Melekhina D, Bazanov D, Bunev A Molecules. 2023; 28(3).

PMID: 36770840 PMC: 9920986. DOI: 10.3390/molecules28031174.


Association Between a Tri-allelic Polymorphism in the Estrogen Metabolism Oxidoreductase NRH:Quinone Oxidoreductase 2 Gene and Risk of Breast Cancer by Molecular Subtype.

Zhou J, Zhu S, He Y, Yu K Front Genet. 2021; 12:658285.

PMID: 33777113 PMC: 7994273. DOI: 10.3389/fgene.2021.658285.


References
1.
Nosjean O, Ferro M, Coge F, Beauverger P, Henlin J, Lefoulon F . Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000; 275(40):31311-7. DOI: 10.1074/jbc.M005141200. View

2.
Gaikwad N, Rogan E, Cavalieri E . Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med. 2007; 43(9):1289-98. PMC: 2064005. DOI: 10.1016/j.freeradbiomed.2007.07.021. View

3.
Nosjean O, Nicolas J, Klupsch F, Delagrange P, Canet E, Boutin J . Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 . Biochem Pharmacol. 2001; 61(11):1369-79. DOI: 10.1016/s0006-2952(01)00615-3. View

4.
Beck J, Colgrave M, Ralph S, Sheil M . Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom Rev. 2001; 20(2):61-87. DOI: 10.1002/mas.1003. View

5.
Winski S, Faig M, Bianchet M, Siegel D, Swann E, Fung K . Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry. 2001; 40(50):15135-42. DOI: 10.1021/bi011324i. View